Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels

BEAM-302 is Beam's lead genetic disease program for liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease.